26 Nov

Change of Directors Interest - S Biggins

Appendix 3Y Change of Director’s Interest Notice + See cha pter 19 for defined terms. 01/0 1/2011 Appendix 3Y Pag e 1 Rule 3.19A.2 Appendix 3Y Change of Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/ 0 9/01 Amended 01/01/11 Name of entity Core Lithium L t d ABN 80 146 287 809 We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act. Nam e of Dir ector Stephen BIGGINS Date of last notice 5 November 20 2 1 Part 1 - Change of director’s relevant interests in securities In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust Note: In th e ca s e o f a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part. Direct or indirect interest Indirect Nature of indirect interest (including registered holder) Note: Pro v id e details of the circumstances giving rise to the relevant interest. 1. Mr Biggins is a director of and has a beneficial interest in the registered holder Nowak Investments Pty Ltd ATF The Nowak Superannuation Fund (Nowak) 2. Mr Biggins is a director of and ha s a beneficial interest in the registered holder Genex Resources Pty Ltd ATF Biggins Resources Family Trust (Genex) Date of change 26 November 20 2 1 Appendix 3Y Change of Director’s Interest No tice + See chapt er 19 for defined term s. Appendix 3Y Page 2 01/01/2011 No. of securities held prior to change 979 , 68 0 Shares h e ld by Nowak 2,2 2 6,667 Shares held by Gen ex 6 , 5 0 0,000 Performance Rights expiring at various times to 30 J une 20 2 6 held by Genex . 2,166,666 vested Performance Rights expiring at 30 J une 20 2 3 held by Genex . 2 , 031 ,666 vested Performance Rights expiring a t 30 J une 20 2 4 held by Genex . 5,0 00,0 00 Op tions held by Genex Class Shares - Fully paid ordinary shares. Performance Rights – unquoted performance rights subject to satisfaction of performa nce conditions . Options - un quoted options with an exercise price of 6.0 cents each and expi ry of 30 June 2023 . Number acq uir ed 750,000 Performance Rights Number disposed Nil Value/Consideration Note: If consideration is non - cash, provide details an d estimat ed valuation $ Nil No. of securities held after change 979 , 68 0 Shares h e ld by Nowak 2,2 2 6,667 Shares h eld by Gen ex 7 , 2 5 0 ,000 Performance Rights expiring at various times to 30 J une 20 2 6 held by Genex . 2,166,666 vested Performance Rights expiring at 30 J une 20 2 3 held by Genex . 2 , 031 ,666 vested Performance Rights expiring a t 30 J une 20 2 4 held by Genex . 5 ,0 00,0 00 Op tions held by Genex Appendix 3Y Change of Director’s Interest Notice + See cha pter 19 for defined terms. 01/0 1/2011 Appendix 3Y Pag e 3 Nature of change Exampl e: on - market trade, off - market trade, exercise of options, issue of securities under dividend rei nve stm ent plan, participation in buy - back Issue of Performance Ri ghts as approved by shareholders at th e 2021 AGM. Part 2 – Chan g e of director’s interests in contracts Note: In t he case of a company, interests which come within paragraph (ii) of the def ini tio n of “notifiable interest of a directo r” should be disclosed in this part. Detail of contract No t ap plicable Nature of int e rest Name of registered holder (if issued secu rit ies) Date of change No. and class of securities to which interest r ela ted prior to change Note: Details are onl y required for a contract in re latio n to which the interest has changed Interest ac q uired Interest disposed Value/Consideration No te: If consideration is non - cash, provide details and an estimated valuatio n Interest after c hange Part 3 – + Clo sed period Were the interests in th e securities or contrac ts d etailed above traded du r ing a + closed period where prior written clearance wa s required? Not applicable If so, was prior written clearance provided to all ow the trade to proceed during this pe riod? If prior written cleara nce w as provided, on what da te w as this provided?
Information on this Website is provided for general information purposes only and is not a substitute for professional advice. ASX Information (including company announcements and prices) is delayed by at least 20 minutes. JSE Information (including company announcements and prices) is delayed by at least 15 minutes. Reliance on the information you access on or from this Website is solely at your own risk. We make no representation or warranty in relation to the future performance of the companies that appear on this Website. Investment in securities involves risk and you should obtain independent professional legal, financial, investment or company advice before acting on any of the information you access on this Website. Using, browsing or otherwise accessing this Website is subject to our Terms and Conditions and our Privacy Policy.

© 2021 Listcorp. ABN 60 166 140 307

Never miss news from Core Lithium Ltd (ASX:CXO) when you join Listcorp.